Please login to the form below

Not currently logged in
Email:
Password:

Imfinzi

This page shows the latest Imfinzi news and features for those working in and with pharma, biotech and healthcare.

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

POSEIDON is comparing triple therapy with Imfinzi, tremelimumab and chemotherapy to Imfinzi plus chemotherapy as well as chemotherapy alone. ... Meanwhile, the PEARL trial is pitting Imfinzi against chemotherapy in first-line NSCLC.

Latest news

More from news
Approximately 15 fully matching, plus 59 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way ... Of course, AstraZeneca isn’t immune to the setbacks of old –

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Open-minded culture. Like the new HQ’s construction, there have been setbacks – such as the setback to its Imfinzi tremelimumab immunotherapy combination in the MYSTIC lung cancer trial last year –

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    Its Imfinzi has secured the first-ever US and EU approval in locally- advanced, unresectable non-small cell lung cancer – a potentially game-changing early use which could have enormous potential

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    And AZ’s Imfinzi (durvalumab) meanwhile has shown its worth as a maintenance therapy to stop recurrence of earlier-stage, locally-advanced NSCLC. ... For instance, AZ’s MYSTIC of Imfinzi and CTLA4 drug tremelimumab in lung cancer wasn’t able to

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics